Publication
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Journal Paper/Review - Feb 11, 2014
Filipits Martin, Bauernhofer Thomas, Hubalek Michael, Knauer Michael, Trapl Harald, Fesl Christian, Schaper Carl, Ferree Sean, Liu Shuzhen, Cowens J Wayne, Gnant Michael, Dubsky Peter, Mlineritsch Brigitte, Singer Christian F, Nielsen Torsten O, Rudas Margaretha, Greil Richard, Stöger Herbert, Jakesz Raimund, Bago-Horvath Zsuzsanna, Dietze Otto, Regitnig Peter, Gruber-Rossipal Christine, Müller-Holzner Elisabeth, Austrian Breast and Colorectal Cancer Study Group
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Print
Pages
Brief description/objective
PURPOSE
To assess the prognostic value of the PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large cohort of postmenopausal, endocrine-responsive breast cancer patients.
EXPERIMENTAL DESIGN
The PAM50 assay was performed on formalin-fixed paraffin-embedded whole-tumor sections of patients who had been enrolled in the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-8). RNA expression levels of the PAM50 genes were determined centrally using the nCounter Dx Analysis System. Late distant recurrence-free survival (DRFS) was analyzed using Cox models adjusted for clinical and pathologic parameters.
RESULTS
PAM50 analysis was successfully performed in 1,246 ABCSG-8 patients. PAM50 ROR score and ROR-based risk groups provided significant additional prognostic information with respect to late DRFS compared with a combined score of clinical factors alone (ROR score: ΔLRχ(2) 15.32, P < 0.001; ROR-based risk groups: ΔLRχ(2) 14.83, P < 0.001). Between years 5 and 15, we observed an absolute risk of distant recurrence of 2.4% in the low ROR-based risk group, as compared with 17.5% in the high ROR-based risk group. The DRFS differences according to the PAM50 ROR score were observed for both node-positive and node-negative disease.
CONCLUSION
PAM50 ROR score and ROR-based risk groups can differentiate patients with breast cancer with respect to their risk for late distant recurrence beyond what can be achieved with established clinicopathologic risk factors.